Quantum BioPharma Receives BUY Rating with $45 Price Target from Kingswood Capital
Quantum BioPharma Ltd. received an independent BUY rating and $45 price target from Kingswood Capital Partners, signaling strong analyst confidence in the company's neurodegenerative disease treatment pipeline and future commercial potential.
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received a significant endorsement from Kingswood Capital Partners, which initiated coverage with a BUY rating and a US$45 price target. The valuation, based on discounted cash flow analysis, assumes successful Phase 2 and 3 trials of the company's lead candidate Lucid-MS between 2026 and 2028, followed by a commercial launch in 2029.
The research report, led by Kingswood Senior Equity Analyst Karen Sterling, PhD, CFA, represents an independent assessment of Quantum BioPharma's potential. The coverage was prepared without compensation from the company, adding credibility to the positive outlook. Quantum BioPharma is developing treatments for neurodegenerative, metabolic, and alcohol misuse disorders, with Lucid-MS being its most advanced candidate.
Lucid-MS is a patented new chemical entity that has demonstrated the ability to prevent and reverse myelin degradation in preclinical models. Myelin degradation is the underlying mechanism of multiple sclerosis, making this development particularly significant for patients suffering from this challenging neurodegenerative condition. The company's progress can be tracked through its official newsroom at https://ibn.fm/QNTM.
Beyond its pharmaceutical developments, Quantum BioPharma maintains additional revenue streams through its ownership stake in Unbuzzd Wellness Inc. The company retains 20.11% ownership as of March 31, 2025, and receives royalty payments of 7% of sales from the unbuzzd(TM) product until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma also maintains full rights to develop similar products for pharmaceutical and medical applications.
The positive analyst coverage from Kingswood Capital Partners suggests growing institutional confidence in Quantum BioPharma's business model and development pipeline. For investors seeking additional information, the full press release is available at https://ibn.fm/S27oE. The company's strategic positioning in both pharmaceutical development and complementary wellness products creates a diversified approach to addressing complex medical conditions while generating multiple potential revenue streams.